Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834043 | 1.00 | PIK3CD (0.32) | PIK3CDLMNACYP3A4GAACYP2C9 | |
| SCHEMBL19011626 | 0.94 | LMNA (0.34) | PIK3CDLMNACYP3A4GAACYP2C9 | |
| SCHEMBL25982050 | 0.86 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL17916222 | 0.83 | — | — | |
| SCHEMBL18295433 | 0.76 | LMNA (0.31) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL18291917 | 0.76 | LMNA (0.34) | LMNACYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL16480382 | 0.76 | KMT2A (0.33) | CHI3L1 | |
| SCHEMBL10722762 | 0.76 | HTT (0.35) | CHI3L1 | |
| SCHEMBL24926308 | 0.76 | KMT2A (0.33) | CHI3L1 | |
| SCHEMBL25962808 | 0.75 | LMNA (0.33) | PIK3CDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | PIK3CD 232/4885LMNA 1904/4885CYP3A4 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.